The arrival of a range of generic drug products onto the French market, backed by the government's health care cost-cutting strategy, has highlighted the lack of a proper legal and economic framework for the distribution of these products in the 23,000 or so state-registered pharmacies.
Bernard Capdeville, president of the pharmacy unions federation, the FSPF, says pharmacists are ready to deliver generics to the marketplace if their delivery is "manageable," and that means supplementary government regulation. Otherwise, he adds, there will be "disorder," which will not be to anyone's benefit.
However, Mr Capdeville adds that pharmacists have no real interest in supplying cheaper drug products if their remuneration is not revised, since their payment is a fraction of the price of drugs. They are also blocked in legislation terms at present from substituting an alternative drug for the one prescribed without the agreement of the prescribing doctor, especially in urgent cases. These are seen as considerable obstacles at a time when 396 different generic forms are available and when no pharmacy can stock every item.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze